Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi (lecanemab-irmb) after the US Food and Drug Administration (FDA) ...

Advisory group guidance enables nonprofit to be at the forefront of Alzheimer's research WELLESLEY HILLS, MA / ACCESSWIRE / ...

Around 20% of Allegheny County’s population is 65 and older, according to recent studies, placing among the highest ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according to a report. The report by GlobalData, a data and analytics company, showed ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...

People in the United States are living longer and with that comes increased rates of dementia. Dr. Josef Coresh, with NYU ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

In a simulated trial, the Florey Dementia Index achieved mean absolute errors of 1.57 and 0.70 years for predicting mild cognitive impairment and Alzheimer's disease onset, respectively ...

The Tennessee Lady Volunteers are set to host its annual “We Back Pat” game at Food City Center on Thursday against ...

Topline results from a phase 2b/3 clinical trial of blarcamesine for individuals with early-stage Alzheimer’s disease showed ...

During the winter months, it is crucial to be extra mindful of loved ones with Alzheimer's and dementia. According to the ...

Passage Bio’s workforce reduction could affect about 32 people, leaving the company with 26 employees as it continues ...